CMS(00867): The innovative drug phosphorus kitotinib cream has been approved for the Chinese market, becoming the first and only targeted therapy approved for the treatment of vitiligo in China.

CMS(00867) announced that its subsidiary, Demit Medical Limited ("Demit Medical"), a innovative pharmaceutical company specializing in skin health, is applying for an independent listing on the main board of the Hong Kong Stock Exchange. On January 30, 2026, Demit Medical obtained approval from the China National Medical Products Administration (NMPA) for its new drug application (NDA) for phosphatidylinositol-lysine-niacinamide phosphatidylcholine cream (indications for vitiligo). The product is for the treatment of non-segmental vitiligo in children aged 12 and above and adult patients with facial involvement. It is the first and only targeted drug approved in China for the treatment of vitiligo, meeting a huge unmet clinical need.